Zeo ScientifiX, Pluri Ink Strategic Deal for Regenerative Medicine Platform
Zeo ScientifiX, Inc. (ZEOX) and Pluri Inc. (PLUR) announced a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity markets. The partnership combines Pluri's cell technology and clinical development expertise with Zeo's established U.S. biologics manufacturing capabilities and physician network. Under the agreement, Pluri will grant Zeo rights to its regenerative medicine assets, and Zeo will issue shares representing 50% ownership of the company to Pluri post-closing. The deal also includes exclusive U.S. rights to Pluri's CellaV aesthetic product line. The transaction is expected to close in the fourth quarter of 2026.
Key Highlights
- Zeo ScientifiX and Pluri Inc. enter definitive strategic agreement to expand U.S. manufacturing and commercialization platform.
- Partnership combines Pluri's cell technology and clinical experience with Zeo's manufacturing and physician network.
- Pluri to grant Zeo rights to regenerative medicine assets; Zeo to issue shares representing 50% ownership of Pluri post-closing.
- Agreement includes exclusive U.S. rights to Pluri's CellaV aesthetic product line.
- Transaction expected to close in Q4 2026, subject to customary conditions.
- Following closing, Zeo's financial results are expected to be consolidated into Pluri's financial statements.
Price Impact
More from ZEOX